Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2000-11-14
2002-02-19
Fay, Zohreh (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S215000, C514S221000, C514S249000
Reexamination Certificate
active
06348485
ABSTRACT:
This application is the National Stage of International Application No. PCT/JP99/03057, filed on Jun. 8, 1999.
1. Technical field
The present invention relates to a pharmaceutical composition for treating or preventing sleep disorders which comprises (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethyl]propionamide in combination with at least one active component selected from zolpidem, zopiclone, triazolam and brotizolam.
2. Background art
Sleep disorders can be classified into about 90 different types based on features of the symptoms, cause of the disease, etc. (International Classification of Sleep Disorders (ICSD): In Diagnostic and Coding Manual; American Sleep Disorder Association: Allen Press Inc.: Lawrence, Kans., 1990). Most of the medicines for treating these disorders at present are benzodiazepines and their derivatives. Non-benzodiazepines such as zolpidem, zopiclone, etc., which are comparatively new hypnotics, are structurally different from benzodiazepines, but exhibit the same activities as benzodiazepines through benzodiazepine receptors. It is believed that benzodiazepines lower the activity of information processing by sedating the limbic system and hypothalamus and inducing sleep. Further, it is known that benzodiazepines do not increase REM (rapid eye movement) sleep and increase non-REM sleep only.
On the other hand, it is disclosed in WO 97/32871 that various tricyclic compounds including (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethyl]propionamide, have an excellent activity as melatonin agonists and are useful for treating or preventing sleep disorders, etc.
REFERENCES:
patent: 3862149 (1975-01-01), Cotrel et al.
patent: 3987052 (1976-10-01), Hester
patent: 4094984 (1978-06-01), Weber et al.
patent: 4794185 (1988-12-01), Rossey et al.
patent: 5786357 (1998-07-01), Young et al.
patent: 6034239 (2000-03-01), Ohkawa et al.
patent: 6071928 (2000-06-01), Curtis et al.
patent: 0513702 (1992-11-01), None
patent: WO 97/32871 (1997-09-01), None
A. A. Piergies et al., “The effect of co-administration of zolpidem with fluoxetine: pharmacokinetics and pharmacodynamics”, International Journal of Clinical Pharmacology and Therapeutics, vol. 34, No. 4 pp. 178-183(1996).
L. Feerini-Strambi et al., “Effect of Melatonin on Sleep Microstructure: Preliminary Results in Healthy Subjects”, Sleep, vol. 16, No. 8, pp. 744-747 (1993).
Miyamoto Masaomi
Ohkawa Shigenori
Chao Mark
Ramesh Elaine M.
Takeda Chemical Industries Ltd.
LandOfFree
Method for treating or preventing sleep disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treating or preventing sleep disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treating or preventing sleep disorders will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2960393